- Home
- UBS vs MRK Comparison
UBS vs MRK Comparison
Compare UBS & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UBS | MRK |
|---|---|---|
| Founded | 1862 | 2000 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.1B | 281.2B |
| IPO Year | 2014 | 1994 |
Fundamental Metrics
Financial Performance| Metric | UBS | MRK |
|---|---|---|
| Price | $49.17 | $128.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 17 |
| Target Price | $60.30 | ★ $125.59 |
| AVG Volume (30 Days) | 2.2M | ★ 8.6M |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | 1.29% | ★ 3.06% |
| EPS Growth | N/A | ★ 8.01 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $65,011,000,000.00 |
| Revenue This Year | $7.40 | $3.61 |
| Revenue Next Year | $2.83 | $5.41 |
| P/E Ratio | $17.22 | ★ N/A |
| Revenue Growth | N/A | ★ 1.31 |
| 52 Week Low | $33.48 | $76.66 |
| 52 Week High | $51.24 | $125.96 |
Technical Indicators
Market Signals| Indicator | UBS | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 54.32 | 70.38 |
| Support Level | $46.47 | $112.68 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.79 | 3.07 |
| MACD | -0.11 | 0.91 |
| Stochastic Oscillator | 50.78 | 97.44 |
Price Performance
Historical ComparisonAbout UBS UBS Group AG Registered
UBS is a global financial institution built around its core strength in wealth management, serving high and ultra-high-net-worth individuals. In Switzerland, it also operates as a traditional retail and commercial bank. Its investment bank and asset management divisions complement the wealth business, providing tailored solutions to UBS clients while serving third-party customers by leveraging UBS' global reach and expertise.
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).